The Promise and Reality of Pharmacogenetics in Psychiatry (Q51846528)

14 April 2018

title

The Promise and Reality of Pharmacogenetics in Psychiatry (English)

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

10 July 2024

0 references

Peter P. Zandi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:20832660

10 July 2024

Jennifer T. Judy

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:20832660

10 July 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20832660

10 July 2024

publication date

1 December 2010

1 reference

14 April 2018

full work available at URL

https://api.elsevier.com/content/article/PII:S0272271210001198?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

https://api.elsevier.com/content/article/PII:S0272271210001198?httpAccept=text/plain

10 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Clinics in laboratory medicine

10 July 2024

published in

1 reference

14 April 2018

volume

30

1 reference

14 April 2018

issue

4

1 reference

14 April 2018

page(s)

931-974

1 reference

14 April 2018

Serotonin transporter polymorphisms and the occurrence of adverse events during treatment with selective serotonin reuptake inhibitors.

cites work

1 reference

7 July 2024

https://opencitations.net/index/api/v1/citations/10.1097/YIC.0B013E328014822A

Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs

1

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

10 July 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

STEP-BD and bipolar depression: what have we learned?

10 July 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Pharmacogenomics: bench to bedside

10 July 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

selective serotonin reuptake inhibitor

10 July 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines

10 July 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

The role of the primary care physician in patients' adherence to antidepressant therapy.

10 July 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry

10 July 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine

10 July 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Serotonin transporter gene polymorphism and antidepressant response

10 July 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression

10 July 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Efficacy of Paroxetine in Depression Is Influenced by a Functional Polymorphism Within the Promoter of the Serotonin Transporter Gene

10 July 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Evidence for an association between a G-protein beta3-gene variant with depression and response to antidepressant treatment

10 July 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Serotonin-2A-receptor and -transporter polymorphisms: lack of association in patients with major depression

10 July 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Tryptophan hydroxylase gene associated with paroxetine antidepressant activity.

10 July 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity.

10 July 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression

10 July 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

A prospective study of 86 new patients with social anxiety disorder

10 July 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Possible influence of the insertion/deletion polymorphism in the angiotensin I-converting enzyme gene on therapeutic outcome in affective disorders

10 July 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19.

10 July 2024

24

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association study of the 5-HT(6) receptor polymorphism (C267T) and symptomatology and antidepressant response in major depressive disorders

10 July 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity

10 July 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients.

10 July 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders

10 July 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association study of angiotensin I-converting enzyme polymorphism and symptomatology and antidepressant response in major depressive disorders.

10 July 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

A variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxamine

10 July 2024

30

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Moclobemide response in depressed patients: association study with a functional polymorphism in the monoamine oxidase A promoter

10 July 2024

31

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association between -1438G/A promoter polymorphism in the 5-HT(2A) receptor gene and fluvoxamine response in Japanese patients with major depressive disorder.

10 July 2024

32

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Monoamine oxidase: A gene polymorphism, tryptophan hydroxylase gene polymorphism and antidepressant response to fluvoxamine in Japanese patients with major depressive disorder

10 July 2024

33

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI treatment trial outcome

10 July 2024

34

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

No association between the serotonergic polymorphisms and incidence of nausea induced by fluvoxamine treatment

10 July 2024

35

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

SSRIs antidepressant activity is influenced by G beta 3 variants

10 July 2024

36

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study

10 July 2024

37

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline

10 July 2024

38

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Pharmacogenetics of antidepressant medication intolerance

10 July 2024

39

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients

10 July 2024

40

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment

10 July 2024

41

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association study of a brain‐derived neurotrophic‐factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response

10 July 2024

42

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Monoamine oxidase A gene polymorphism, 5-HT 2A receptor gene polymorphism and incidence of nausea induced by fluvoxamine

10 July 2024

43

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder

10 July 2024

44

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Serotonin transporter promoter gene polymorphism and long-term outcome of antidepressant treatment

10 July 2024

45

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression

10 July 2024

46

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Investigation of serotonin-related genes in antidepressant response

10 July 2024

47

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study

10 July 2024

48

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders

10 July 2024

49

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

The C(-1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: preliminary findings

10 July 2024

50

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms.

10 July 2024

51

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

The angiotensin I converting enzyme insertion/deletion polymorphism influences therapeutic outcome in major depressed women, but not in men

10 July 2024

52

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment

10 July 2024

53

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting

10 July 2024

54

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study

10 July 2024

55

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association between a G-protein beta 3 subunit gene polymorphism and the symptomatology and treatment responses of major depressive disorders

10 July 2024

56

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association of the C(-1019)G 5-HT1A functional promoter polymorphism with antidepressant response

10 July 2024

57

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association of a corticotropin-releasing hormone receptor 1 haplotype and antidepressant treatment response in Mexican-Americans

10 July 2024

58

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline

10 July 2024

59

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

The effects of a 5-hydroxytryptamine 1A receptor gene polymorphism on the clinical response to fluvoxamine in depressed patients

10 July 2024

60

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

The dysbindin gene in major depression: an association study

10 July 2024

61

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Evidence for a combined genetic effect of the 5-HT(1A) receptor and serotonin transporter genes in the clinical outcome of major depressive patients treated with citalopram

10 July 2024

62

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

No association between the tryptophan hydroxylase gene polymorphism and major depressive disorders and antidepressant response in a Korean population

10 July 2024

63

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression

10 July 2024

64

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Serotonin receptor 2A gene polymorphism (-1438A/G) and short-term treatment response to citalopram

10 July 2024

65

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Lack of association of TPH2 exon XI polymorphisms with major depression and treatment resistance.

10 July 2024

66

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism.

10 July 2024

67

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Sequence analysis of the serotonin transporter and associations with antidepressant response

10 July 2024

68

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association between the 5-HT6 receptor C267T polymorphism and response to antidepressant treatment in major depressive disorder

10 July 2024

69

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association study of a monoamine oxidase a gene promoter polymorphism with major depressive disorder and antidepressant response

10 July 2024

70

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment

10 July 2024

71

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin

10 July 2024

72

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder.

10 July 2024

73

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients.

10 July 2024

74

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine

10 July 2024

75

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Serotonin transporter gene-linked polymorphic region: possible pharmacogenetic implications of rare variants

10 July 2024

76

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association study of two serotonin 1A receptor gene polymorphisms and fluoxetine treatment response in Chinese major depressive disorders

10 July 2024

77

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Serotonin 2A -1438 G/A and G-protein Beta3 subunit C825T polymorphisms in patients with depression and SSRI-associated sexual side-effects

10 July 2024

78

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder

10 July 2024

79

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Serotonin transporter polymorphisms and clinical response to sertraline across ethnicities

10 July 2024

80

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Serotonin transporter polymorphisms and side effects in antidepressant therapy--a pilot study

10 July 2024

81

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

The effect of 5-hydroxytryptamine 3A and 3B receptor genes on nausea induced by paroxetine

10 July 2024

82

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Polymorphisms in the 5-hydroxytryptamine 2A receptor and CytochromeP4502D6 genes synergistically predict fluvoxamine-induced side effects in japanese depressed patients

10 July 2024

83

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression

10 July 2024

84

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study.

10 July 2024

85

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association between the tryptophan hydroxylase-1 gene A218C polymorphism and citalopram antidepressant response in a Korean population.

10 July 2024

86

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression

10 July 2024

87

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment.

10 July 2024

88

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Assessment of human serotonin 1A receptor polymorphisms and SSRI responsiveness

10 July 2024

89

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample

10 July 2024

90

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association study of the serotonin transporter promoter polymorphism and mirtazapine antidepressant response in major depressive disorder

10 July 2024

91

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Relationship between G-protein beta-3 subunit C825T polymorphism and mirtazapine responses in Korean patients with major depression

10 July 2024

92

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

No association of TPH1 218A/C polymorphism with treatment response and intolerance to SSRIs in Japanese patients with major depression.

10 July 2024

93

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Serotonin transporter polymorphism (5-HTTLPR) and citalopram effectiveness and side effects in children with depression and/or anxiety disorders

10 July 2024

94

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Genetic markers of suicidal ideation emerging during citalopram treatment of major depression

10 July 2024

95

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association study of corticotropin-releasing hormone receptor1 gene polymorphisms and antidepressant response in major depressive disorders

10 July 2024

96

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort

10 July 2024

97

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Dysbindin associated with selective serotonin reuptake inhibitor antidepressant efficacy

10 July 2024

98

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment

10 July 2024

99

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

The MAOA T941G polymorphism and short-term treatment response to mirtazapine and paroxetine in major depression.

10 July 2024

101

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Lack of supporting evidence for a genetic association of the FKBP5 polymorphism and response to antidepressant treatment

10 July 2024

102

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

A splice site polymorphism in the G-protein beta subunit influences antidepressant efficacy in depression

10 July 2024

103

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine

10 July 2024

104

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Lithium overcomes the influence of 5-HTTLPR gene polymorphism on antidepressant response to sleep deprivation

10 July 2024

105

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Serotonin transporter genotype interacts with paroxetine plasma levels to influence depression treatment response in geriatric patients

10 July 2024

106

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression

10 July 2024

107

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample

10 July 2024

108

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Serotonin receptor 1A-1019C/G variant: impact on antidepressant pharmacoresponse in melancholic depression?

10 July 2024

109

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association study of paroxetine therapeutic response with SERT gene polymorphisms in patients with major depressive disorder.

10 July 2024

110

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response

10 July 2024

111

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

A brain-derived neurotrophic factor (BDNF) haplotype is associated with antidepressant treatment outcome in mood disorders.

10 July 2024

112

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder.

10 July 2024

113

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Antidepressant response and intolerance to SSRI is not influenced by G-protein beta3 subunit gene C825T polymorphism in Japanese major depressive patients.

10 July 2024

114

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

The FKBP5-gene in depression and treatment response--an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort

10 July 2024

115

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

MDR1 gene polymorphism: therapeutic response to paroxetine among patients with major depression

10 July 2024

116

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

The influence of 5-HTTLPR and STin2 polymorphisms in the serotonin transporter gene on treatment effect of selective serotonin reuptake inhibitors in depressive patients

10 July 2024

117

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nausea

10 July 2024

118

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Influence of the tyrosine hydroxylase val81met polymorphism and catechol-O-methyltransferase val158met polymorphism on the antidepressant effect of milnacipran

10 July 2024

119

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

The association of serotonin transporter genotypes and selective serotonin reuptake inhibitor (SSRI)-associated sexual side effects: possible relationship to oral contraceptives

10 July 2024

120

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy

10 July 2024

121

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Dysbindin gene (DTNBP1) in major depression: association with clinical response to selective serotonin reuptake inhibitors

10 July 2024

122

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association study of phosphodiesterase genes in the Sequenced Treatment Alternatives to Relieve Depression sample

10 July 2024

123

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Brain-derived neurotrophic factor ( BDNF) gene: no major impact on antidepressant treatment response

10 July 2024

124

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder.

10 July 2024

126

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

SLC6A4 variation and citalopram response

10 July 2024

127

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder

10 July 2024

128

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Genetic and clinical predictors of sexual dysfunction in citalopram-treated depressed patients

10 July 2024

129

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Antidepressive-drug-induced bodyweight gain is associated with polymorphisms in genes coding for COMT and TPH1.

10 July 2024

130

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Genome-wide association study of suicidal ideation emerging during citalopram treatment of depressed outpatients

10 July 2024

131

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

A genomewide association study of citalopram response in major depressive disorder

10 July 2024

132

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression

10 July 2024

133

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Some aspects of genetic polymorphism in the biotransformation of antidepressants

10 July 2024

134

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity

10 July 2024

135

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs

10 July 2024

136

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes

10 July 2024

137

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19.

10 July 2024

138

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

The evolution of drug metabolism

10 July 2024

139

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

AmpliChip CYP450 test: personalized medicine has arrived in psychiatry.

10 July 2024

140

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Review of evidence for genetic testing for CYP450 polymorphisms in management of patients with nonpsychotic depression with selective serotonin reuptake inhibitors

10 July 2024

141

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Allelic Variation of Human Serotonin Transporter Gene Expression

10 July 2024

142

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder

10 July 2024

143

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Serotonin transporter promoter and intron 2 polymorphisms: relationship between allelic variants and gene expression

10 July 2024

144

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients

10 July 2024

145

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder

10 July 2024

146

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Synthesis of serotonin by a second tryptophan hydroxylase isoform

10 July 2024

147

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Late developmental stage-specific role of tryptophan hydroxylase 1 in brain serotonin levels.

10 July 2024

148

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Brain-derived neurotrophic factor

10 July 2024

149

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

The history of lithium therapy

10 July 2024

150

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

A critical appraisal of lithium's efficacy and effectiveness: the last 60 years

10 July 2024

151

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Lithium in mood disorders: increasing evidence base, declining use?

10 July 2024

152

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Maintenance treatment in bipolar disorder: a reassessment of lithium as the first choice

10 July 2024

153

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Lithium-responsive affective disorders: no association with the tyrosine hydroxylase gene

10 July 2024

154

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

No association between chromosome-18 markers and lithiumresponsive affective disorders

10 July 2024

155

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Evidence for a role of phospholipase C-gamma1 in the pathogenesis of bipolar disorder

10 July 2024

157

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

MN blood groups and bipolar disorder: evidence of genotypic association and Hardy-Weinberg disequilibrium

10 July 2024

158

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

The polymorphic inositol polyphosphate 1-phosphatase gene as a candidate for pharmacogenetic prediction of lithium-responsive manic-depressive illness

10 July 2024

159

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Dopamine receptor D3 gene and response to lithium prophylaxis in mood disorders

10 July 2024

160

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Dopamine receptor D2 and D4 genes, GABA(A) alpha-1 subunit genes and response to lithium prophylaxis in mood disorders.

10 July 2024

162

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Tryptophan hydroxylase gene and response to lithium prophylaxis in mood disorders11This work was partially supported by the BIOMED 2 grant BMH4-CT97-2307

10 July 2024

163

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association and linkage studies of CRH and PENK genes in bipolar disorder: a collaborative IGSLI study

10 July 2024

165

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Serotonin receptor 2A, 2C, 1A genes and response to lithium prophylaxis in mood disorders

10 July 2024

166

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Identification of three polymorphisms in the translated region of PLC-gamma1 and their investigation in lithium responsive bipolar disorder.

10 July 2024

167

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Serotonin transporter gene associated with lithium prophylaxis in mood disorders.

10 July 2024

168

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

The phospholipase C-gamma1 gene (PLCG1) and lithium-responsive bipolar disorder: re-examination of an intronic dinucleotide repeat polymorphism

10 July 2024

169

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Pharmacogenetics of lithium prophylaxis in mood disorders: analysis of COMT, MAO-A, and Gbeta3 variants

10 July 2024

170

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Possible relationship between mitochondrial DNA polymorphisms and lithium response in bipolar disorder

10 July 2024

171

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association studies of 5-HT2A and 5-HT2C serotonin receptor gene polymorphisms with prophylactic lithium response in bipolar patients

10 July 2024

172

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Prophylactic lithium response and polymorphism of the brain-derived neurotrophic factor gene.

10 July 2024

173

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Prophylactic effect of lithium in bipolar affective illness may be related to serotonin transporter genotype

10 July 2024

174

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Long-term response to lithium salts in bipolar illness is influenced by the glycogen synthase kinase 3-beta -50 T/C SNP.

10 July 2024

175

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association study of the glycogen synthase kinase-3beta gene polymorphism with prophylactic lithium response in bipolar patients.

10 July 2024

176

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Lithium response and Val66Met polymorphism of the brain-derived neurotrophic factor gene in Japanese patients with bipolar disorder

10 July 2024

177

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

A possible association between the -116C/G single nucleotide polymorphism of the XBP1 gene and lithium prophylaxis in bipolar disorder

10 July 2024

178

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association study of the INPP1, 5HTT, BDNF, AP-2beta and GSK-3beta GENE variants and restrospectively scored response to lithium prophylaxis in bipolar disorder

10 July 2024

179

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

No association between the PREP gene and lithium responsive bipolar disorder

10 July 2024

180

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

The pharmacogenetics of lithium response depends upon clinical co-morbidity.

10 July 2024

181

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Response to lithium prophylaxis: interaction between serotonin transporter and BDNF genes

10 July 2024

182

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Lithium response and genetic variation in the CREB family of genes

10 July 2024

183

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association studies of the BDNF and the NTRK2 gene polymorphisms with prophylactic lithium response in bipolar patients

10 July 2024

184

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

A possible association between missense polymorphism of the breakpoint cluster region gene and lithium prophylaxis in bipolar disorder

10 July 2024

185

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Preliminary evidence on the association between XBP1-116C/G polymorphism and response to prophylactic treatment with valproate in bipolar disorders.

10 July 2024

186

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

No association of three GRIN2B polymorphisms with lithium response in bipolar patients.

10 July 2024

187

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

The association study of three FYN polymorphisms with prophylactic lithium response in bipolar patients

10 July 2024

188

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Dopamine D1 receptor gene polymorphism is associated with prophylactic lithium response in bipolar disorder

10 July 2024

189

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

A genomewide association study of response to lithium for prevention of recurrence in bipolar disorder.

10 July 2024

190

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Neural and developmental actions of lithium: a unifying hypothesis

10 July 2024

191

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Lithium and bipolar mood disorder: the inositol-depletion hypothesis revisited

10 July 2024

192

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

A molecular mechanism for the effect of lithium on development

10 July 2024

193

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Lithium therapy and signal transduction.

10 July 2024

194

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Mood stabilizers, glycogen synthase kinase-3beta and cell survival

10 July 2024

195

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3.

10 July 2024

196

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Brain contains two forms of synaptic vesicle protein 2

10 July 2024

197

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Deciphering the lithium transcriptome: microarray profiling of lithium-modulated gene expression in human neuronal cells

10 July 2024

198

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

The mammalian Odz gene family: homologs of a Drosophila pair-rule gene with expression implying distinct yet overlapping developmental roles

10 July 2024

199

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

A history of antipsychotic drug development

10 July 2024

200

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

10 July 2024

201

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

10 July 2024

202

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Side effects as influencers of treatment outcome

10 July 2024

203

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association between clozapine response and allelic variation in 5-HT2A receptor gene

10 July 2024

204

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Cytochrome P4502D6 genotype does not determine response to clozapine

10 July 2024

205

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Genetic variation of 5-HT2A receptor and response to clozapine

10 July 2024

206

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Genetic variation of the 5-HT2A receptor and response to clozapine

10 July 2024

207

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Lack of association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine

10 July 2024

209

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine

10 July 2024

210

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Assessment of association of D3 dopamine receptor MscI polymorphism with schizophrenia: analysis of symptom ratings, family history, age at onset, and movement disorders

10 July 2024

211

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Efficacy and side-effects of clozapine: testing for association with allelic variation in the dopamine D4 receptor gene

10 July 2024

213

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Efficacy and side-effects of clozapine not associated with variation in the 5-HT2C receptor

10 July 2024

214

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients

10 July 2024

215

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

An association between clozapine-induced agranulocytosis in schizophrenics and HLA-DQB1*0201.

10 July 2024

217

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine.

10 July 2024

218

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Dopamine D4 receptor gene polymorphisms and neuroleptic response in schizophrenia

10 July 2024

219

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients.

10 July 2024

220

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

HLA-B38 and clozapine-induced agranulocytosis in Israeli Jewish schizophrenic patients

10 July 2024

221

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Failure to respond to treatment with typical antipsychotics is not associated with CYP2D6 ultrarapid hydroxylation.

10 July 2024

222

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia

10 July 2024

223

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Polymorphisms of the dopamine D4 receptor and response to antipsychotic drugs.

10 July 2024

224

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

T102C polymorphism in the 5HT2A gene and schizophrenia: relation to phenotype and drug response variability

10 July 2024

225

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

No evidence for association of serotonin-2A receptor variant (102T/C) with schizophrenia or clozapine response in a Chinese population

10 July 2024

226

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakistani patients

10 July 2024

227

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia

10 July 2024

228

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Serotonin-6 receptor variant (C267T) and clinical response to clozapine

10 July 2024

229

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Pharmacogenetic prediction of clozapine response

10 July 2024

230

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

The serotonin transporter and clozapine response

10 July 2024

231

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia.

10 July 2024

232

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association analysis of the 5-HT5A gene in depression, psychosis and antipsychotic response

10 July 2024

233

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

No influence of adrenergic receptor polymorphisms on schizophrenia and antipsychotic response

10 July 2024

234

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Tardive dyskinesia is not associated with the serotonin gene polymorphism (5-HTTLPR) in Chinese

10 July 2024

235

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Clozapine-induced agranulocytosis and hereditary polymorphisms of clozapine metabolizing enzymes: no association with myeloperoxidase and cytochrome P4502D6

10 July 2024

236

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association of dopamine D3-receptor gene variants with neuroleptic induced akathisia in schizophrenic patients: a generalization of Steen's study on DRD3 and tardive dyskinesia

10 July 2024

237

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

DRD3 and DAT1 genes in schizophrenia: an association study

10 July 2024

238

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association between the methylenetetrahydrofolate reductase 677C-->T missense mutation and schizophrenia

10 July 2024

239

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Dopamine D4 receptor 48-bp repeat polymorphism: no association with response to antipsychotic treatment, but association with catatonic schizophrenia.

10 July 2024

240

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Brain Derived Neurotrophic Factor (BDNF) gene variants association with age at onset and therapeutic response in schizophrenia

10 July 2024

241

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Homozygosity for the Gly-9 variant of the dopamine D3 receptor and risk for tardive dyskinesia in schizophrenic patients.

10 July 2024

242

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

No relationship between Taq1 a polymorphism of dopamine D(2) receptor gene and extrapyramidal adverse effects of selective dopamine D(2) antagonists, bromperidol, and nemonapride in schizophrenia: a preliminary study

10 July 2024

243

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Dopamine D3 receptor variant and tardive dyskinesia

10 July 2024

244

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients

10 July 2024

245

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility.

10 July 2024

246

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association study of a functional serotonin transporter gene polymorphism with schizophrenia, psychopathology and clozapine response

10 July 2024

247

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia

10 July 2024

248

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle

10 July 2024

249

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Genetic polymorphisms of the dopamine D2 and D3 receptor and neuroleptic drug effects in schizophrenic patients

10 July 2024

250

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Genetic determinants of clozapine-induced agranulocytosis: recent results of HLA subtyping in a non-jewish caucasian sample.

10 July 2024

251

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients

10 July 2024

252

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Genetic variants of the serotonin system and weight change during clozapine treatment

10 July 2024

253

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association analysis for NMDA receptor subunit 2B (GRIN2B) genetic variants and psychopathology and clozapine response in schizophrenia

10 July 2024

254

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association between three functional polymorphisms of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia

10 July 2024

255

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Serotonin transporter polymorphisms: no association with response to antipsychotic treatment, but associations with the schizoparanoid and residual subtypes of schizophrenia

10 July 2024

256

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association between the Ser9Gly polymorphism of the dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients

10 July 2024

257

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Lack of association between the T-->C 267 serotonin 5-HT6 receptor gene (HTR6) polymorphism and prediction of response to clozapine in schizophrenia

10 July 2024

258

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

No relationship between--141C Ins/Del polymorphism in the promoter region of dopamine D2 receptor and extrapyramidal adverse effects of selective dopamine D2 antagonists in schizophrenic patients: a preliminary study

10 July 2024

259

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients

10 July 2024

260

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene

10 July 2024

261

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Lack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene and tardive dyskinesia in schizophrenia

10 July 2024

262

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia

10 July 2024

263

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association of the TaqI A polymorphism of the dopamine D(2) receptor gene with predisposition to neuroleptic malignant syndrome

10 July 2024

264

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

The -141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients

10 July 2024

265

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Susceptibility to neuroleptic-induced tardive dyskinesia and the T102C polymorphism in the serotonin type 2A receptor

10 July 2024

266

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association analysis of polymorphism in the promoter region of the alpha2a-adrenoceptor gene with schizophrenia and clozapine response

10 July 2024

267

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Evidence for an association between polymorphism in the serotonin-2A receptor variant (102T/C) and increment of N100 amplitude in schizophrenics treated with clozapine.

10 July 2024

268

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain

10 July 2024

269

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment.

10 July 2024

270

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

CYP2D6 polymorphisms and atypical antipsychotic weight gain.

10 July 2024

271

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Novel mutations in 5-HT3A and 5-HT3B receptor genes not associated with clozapine response.

10 July 2024

272

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

The influence on the schizophrenic symptoms by the DRD2Ser/Cys311 and -141C Ins/Del polymorphisms

10 July 2024

273

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia

10 July 2024

274

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene

10 July 2024

275

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism

10 July 2024

276

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Investigation of promoter variants of the histamine 1 and 2 receptors in schizophrenia and clozapine response.

10 July 2024

277

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Tardive dystonia and genetic polymorphisms of cytochrome P4502D6 and dopamine D2 and D3 receptors: a preliminary finding

10 July 2024

278

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Genetic association analysis of 5-HT(6) receptor gene polymorphism (267C/T) with tardive dyskinesia

10 July 2024

279

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism

10 July 2024

280

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a case-control study

10 July 2024

281

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Interactive effect of cytochrome P450 17alpha-hydroxylase and dopamine D3 receptor gene polymorphisms on abnormal involuntary movements in chronic schizophrenia

10 July 2024

282

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Age and the relationship of dopamine D3, serotonin 2C and serotonin 2A receptor genes to abnormal involuntary movements in chronic schizophrenia

10 July 2024

283

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Clinical applications of pharmacogenetics in psychiatry

10 July 2024

284

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

-759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain

10 July 2024

285

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association of the Ser9Gly polymorphism in the dopamine D3 receptor gene with tardive dyskinesia in Korean schizophrenics

10 July 2024

286

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

The increased activity of plasma manganese superoxide dismutase in tardive dyskinesia is unrelated to the Ala-9Val polymorphism.

10 July 2024

287

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association of a polymorphism in the promoter region of the serotonin 5-HT2C receptor gene with tardive dyskinesia in patients with schizophrenia

10 July 2024

288

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Polymorphisms of dopamine receptors and tardive dyskinesia among Chinese patients with schizophrenia

10 July 2024

289

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Tardive dyskinesia is not associated with the polymorphisms of 5-HT2A receptor gene, serotonin transporter gene and catechol-o-methyltransferase gene ⋆

10 July 2024

290

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

An association study of a brain-derived neurotrophic factor Val66Met polymorphism and clozapine response of schizophrenic patients

10 July 2024

291

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Cytochrome P450 II D6 gene polymorphisms and the neuroleptic-induced extrapyramidal symptoms in Japanese schizophrenic patients.

10 July 2024

292

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Lack of association in Japanese patients between neuroleptic malignant syndrome and the TaqI A polymorphism of the dopamine D2 receptor gene

10 July 2024

293

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

CYP2D6 Polymorphism and Tardive Dyskinesia in Schizophrenic Patients

10 July 2024

294

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Relationship between functional dopamine D2 and D3 receptors gene polymorphisms and neuroleptic malignant syndrome

10 July 2024

295

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

NQO2 gene is associated with clozapine-induced agranulocytosis

10 July 2024

296

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain

10 July 2024

297

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

No association of tumor necrosis factor alpha gene polymorphisms with schizophrenia or response to clozapine

10 July 2024

298

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

DRD4 exon III polymorphism and response to risperidone in Israeli adolescents with schizophrenia: a pilot pharmacogenetic study

10 July 2024

299

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Interaction between NOTCH4 and catechol-O-methyltransferase genotypes in schizophrenia patients with poor response to typical neuroleptics

10 July 2024

301

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Interaction of COMT Val108/158 Met Genotype and Olanzapine Treatment on Prefrontal Cortical Function in Patients With Schizophrenia

10 July 2024

302

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

An association study of the neurotensin receptor gene with schizophrenia and clozapine response.

10 July 2024

303

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Neuregulin genotype and medication response in Finnish patients with schizophrenia

10 July 2024

304

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association in Japanese patients between neuroleptic malignant syndrome and functional polymorphisms of the dopamine D(2) receptor gene

10 July 2024

305

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function

10 July 2024

306

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Risperidone response and 5-HT6 receptor gene variance: genetic association analysis with adjustment for nongenetic confounders

10 July 2024

307

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Tardive dyskinesia and DRD2, DRD3, DRD4, 5-HT2A variants in schizophrenia: an association study with repeated assessment

10 July 2024

308

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association analysis of the dopamine D3 receptor gene ser9gly and brain-derived neurotrophic factor gene val66met polymorphisms with antipsychotic-induced persistent tardive dyskinesia and clinical expression in Chinese schizophrenic patients

10 July 2024

309

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Cytochrome P-450 2D6*10 C188T polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in Chinese schizophrenic patients

10 July 2024

310

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Genetic association analysis of functional polymorphisms in the cytochrome P450 1A2 (CYP1A2) gene with tardive dyskinesia in Japanese patients with schizophrenia.

10 July 2024

311

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Polymorphisms of dopamine degradation enzyme (COMT and MAO) genes and tardive dyskinesia in patients with schizophrenia

10 July 2024

312

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Impact of myeloperoxidase and NADPH-oxidase polymorphisms in drug-induced agranulocytosis

10 July 2024

313

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Quinone oxidoreductase (NQO1) gene polymorphism (609C/T) may be associated with tardive dyskinesia, but not with the development of schizophrenia

10 July 2024

314

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Genetic association analysis of neuronal nitric oxide synthase gene polymorphism with tardive dyskinesia

10 July 2024

315

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia

10 July 2024

316

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association study of adrenergic beta3 receptor (Trp64Arg) and G-protein beta3 subunit gene (C825T) polymorphisms and weight change during clozapine treatment

10 July 2024

317

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association analysis of a neural nitric oxide synthase gene polymorphism and antipsychotics-induced tardive dyskinesia in Chinese schizophrenic patients.

10 July 2024

318

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Catechol-O-methyltransferase val108/158met genotype predicts working memory response to antipsychotic medications

10 July 2024

319

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis

10 July 2024

320

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Clozapine-induced weight gain: a study in monozygotic twins and same-sex sib pairs

10 July 2024

321

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Lack of association between two polymorphisms of brain-derived neurotrophic factor and response to typical neuroleptics.

10 July 2024

322

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment.

10 July 2024

323

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation

10 July 2024

324

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness

10 July 2024

325

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Identification of a naturally occurring 21 bp deletion in alpha 2c noradrenergic receptor gene and cognitive correlates to antipsychotic treatment.

10 July 2024

326

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

II. Serotonin receptor gene polymorphisms and their association with tardive dyskinesia among schizophrenia patients from North India.

10 July 2024

327

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine

10 July 2024

328

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Negative symptoms of schizophrenia could explain discrepant data on the association between the 5-HT2A receptor gene and response to antipsychotics

10 July 2024

329

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations

10 July 2024

330

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6.

10 July 2024

331

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Antipsychotics and dopamine transporter gene polymorphisms in delirium patients

10 July 2024

332

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Negative association between catechol-O-methyltransferase (COMT) gene Val158Met polymorphism and persistent tardive dyskinesia in schizophrenia

10 July 2024

333

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Dopamine D3 receptor Ser9Gly polymorphism and risperidone response

10 July 2024

334

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association analysis of NAD(P)Hratioquinone oxidoreductase (NQO1) Pro187Ser genetic polymorphism and tardive dyskinesia in patients with schizophrenia in Taiwan

10 July 2024

335

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Clozapine-induced weight gain associated with the 5HT2C receptor -759C/T polymorphism

10 July 2024

336

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia

10 July 2024

337

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Suggestive association between the C825T polymorphism of the G-protein beta3 subunit gene (GNB3) and clinical improvement with antipsychotics in schizophrenia

10 July 2024

338

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response

10 July 2024

339

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association study between a functional glutathione S-transferase (GSTP1) gene polymorphism (Ile105Val) and tardive dyskinesia

10 July 2024

340

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: I. Association of CYP1A2 gene polymorphism

10 July 2024

341

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms

10 July 2024

342

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Polymorphism of the adrenergic receptor alpha 2a -1291C>G genetic variation and clozapine-induced weight gain

10 July 2024

343

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability

10 July 2024

344

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients

10 July 2024

345

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Dopamine D4 receptor gene exon III polymorphism and interindividual variation in response to clozapine

10 July 2024

346

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients

10 July 2024

348

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Dopamine D2 receptor gene variants and quantitative measures of positive and negative symptom response following clozapine treatment

10 July 2024

349

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

RGS4 genotype is not associated with antipsychotic medication response in schizophrenia.

10 July 2024

350

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients

10 July 2024

351

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

The human dopamine receptor D2 (DRD2) gene is associated with tardive dyskinesia in patients with schizophrenia

10 July 2024

352

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Haplotype analysis of endothelial nitric oxide synthase (NOS3) genetic variants and tardive dyskinesia in patients with schizophrenia

10 July 2024

353

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association between the interleukin-1 receptor antagonist gene and negative symptom improvement during antipsychotic treatment

10 July 2024

354

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Weight gain associated with the alpha2a-adrenergic receptor -1,291 C/G polymorphism and olanzapine treatment

10 July 2024

355

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Effect of 5-HT 1A Receptor Gene Polymorphism on Negative and Depressive Symptom Response to Antipsychotic Treatment of Drug-Naive Psychotic Patients

10 July 2024

356

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Investigation of the phenylalanine hydroxylase gene and tardive dyskinesia

10 July 2024

357

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Genetic association analysis of the glutathione peroxidase (GPX1) gene polymorphism (Pro197Leu) with tardive dyskinesia

10 July 2024

358

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Genetic susceptibility to tardive dyskinesia among schizophrenia subjects: IV. Role of dopaminergic pathway gene polymorphisms

10 July 2024

359

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association of treatment-resistant schizophrenia with the G2677A/T and C3435T polymorphisms in the ATP-binding cassette subfamily B member 1 gene

10 July 2024

360

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: a preliminary study

10 July 2024

361

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Family and case-control association study of the tumor necrosis factor-alpha (TNF-alpha) gene with schizophrenia and response to antipsychotic medication.

10 July 2024

362

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association of the dopamine receptor interacting protein gene, NEF3, with early response to antipsychotic medication.

10 July 2024

363

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia.

10 July 2024

364

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association between 5-HT2A, TPH1 and GNB3 genotypes and response to typical neuroleptics: a serotonergic approach

10 July 2024

365

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

COMT Val158Met polymorphism predicts negative symptoms response to treatment with olanzapine in schizophrenia

10 July 2024

366

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association of serotonin 2A receptor and lack of association of CYP1A2 gene polymorphism with tardive dyskinesia in a Turkish population

10 July 2024

367

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association study of olanzapine-induced weight gain and therapeutic response with SERT gene polymorphisms in female schizophrenic patients

10 July 2024

368

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Possible association of the pro-melanin-concentrating hormone gene with a greater body mass index as a side effect of the antipsychotic olanzapine

10 July 2024

369

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

HTR2C haplotypes and antipsychotics-induced weight gain: X-linked multimarker analysis

10 July 2024

370

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Clozapine-induced agranulocytosis in schizophrenic Caucasians: confirming clues for associations with human leukocyte class I and II antigens

10 July 2024

371

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Polymorphisms in dopamine receptor DRD1 and DRD2 genes and psychopathological and extrapyramidal symptoms in patients on long-term antipsychotic treatment

10 July 2024

372

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Leptin and leptin receptor gene polymorphisms and increases in body mass index (BMI) from olanzapine treatment in persons with schizophrenia

10 July 2024

373

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association of the RGS2 gene with extrapyramidal symptoms induced by treatment with antipsychotic medication.

10 July 2024

374

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients

10 July 2024

375

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association study of four dopamine D1 receptor gene polymorphisms and clozapine treatment response

10 July 2024

376

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Effects of CYP2D6 polymorphisms on neuroleptic malignant syndrome

10 July 2024

377

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

No evidence for an association between G protein beta3 subunit gene C825T polymorphism and tardive dyskinesia in schizophrenia.

10 July 2024

378

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

No Association between Dopamine D4 Receptor Gene –521 C/T Polymorphism and Tardive Dyskinesia in Schizophrenia

10 July 2024

379

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association analysis of polymorphisms in the N-methyl-D-aspartate (NMDA) receptor subunit 2B (GRIN2B) gene and tardive dyskinesia in schizophrenia

10 July 2024

380

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Choline acetyltransferase variants and their influence in schizophrenia and olanzapine response

10 July 2024

381

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Support for an association of the C939T polymorphism in the human DRD2 gene with tardive dyskinesia in schizophrenia.

10 July 2024

382

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Clinical involvement of catechol-O-methyltransferase polymorphisms in schizophrenia spectrum disorders: influence on the severity of psychotic symptoms and on the response to neuroleptic treatment.

10 July 2024

383

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia

10 July 2024

384

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

The association between HTR2C polymorphisms and obesity in psychiatric patients using antipsychotics: a cross-sectional study

10 July 2024

385

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Manganese superoxide dismutase (MnSOD: Ala-9Val) gene polymorphism may not be associated with schizophrenia and tardive dyskinesia

10 July 2024

386

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

-759 C/T polymorphism of 5-HT2C receptor gene and early phase weight gain associated with antipsychotic drug treatment

10 July 2024

387

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Functional polymorphisms of the cytochrome P450 1A2 (CYP1A2) gene and prolonged QTc interval in schizophrenia

10 July 2024

388

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: V. Association of CYP1A2 1545 C>T polymorphism

10 July 2024

389

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association of dopamine receptor polymorphisms with schizophrenia and antipsychotic response in a South Indian population

10 July 2024

390

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Response of risperidone treatment may be associated with polymorphisms of HTT gene in Chinese schizophrenia patients

10 July 2024

391

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients

10 July 2024

392

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association of AKT1 gene polymorphisms with risk of schizophrenia and with response to antipsychotics in the Chinese population

10 July 2024

393

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association of DAOA polymorphisms with schizophrenia and clinical symptoms or therapeutic effects.

10 July 2024

394

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients

10 July 2024

395

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Dopamine transporter polymorphisms and risperidone response in Chinese schizophrenia patients: an association study.

10 July 2024

396

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association of clozapine-induced weight gain with a polymorphism in the leptin promoter region in patients with chronic schizophrenia in a Chinese population

10 July 2024

397

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study

10 July 2024

398

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients

10 July 2024

399

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective disorder

10 July 2024

400

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Pharmacogenetics of parkinsonism, rigidity, rest tremor, and bradykinesia in African-Caribbean inpatients: differences in association with dopamine and serotonin receptors

10 July 2024

401

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Excess of transmission of the G allele of the -1438A/G polymorphism of the 5-HT2A receptor gene in patients with schizophrenia responsive to antipsychotics

10 July 2024

402

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Ethnic stratification of the association of RGS4 variants with antipsychotic treatment response in schizophrenia.

10 July 2024

403

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

CYP2D6*3, *4, *5 AND *6 POLYMORPHISMS AND ANTIPSYCHOTIC-INDUCED EXTRAPYRAMIDAL SIDE-EFFECTS IN PATIENTS RECEIVING ANTIPSYCHOTIC THERAPY

10 July 2024

404

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Exploring genetic variations that may be associated with the direct effects of some antipsychotics on lipid levels.

10 July 2024

405

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes

10 July 2024

406

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants

10 July 2024

407

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association between a polymorphism of the HTR3A gene and therapeutic response to risperidone treatment in drug-naive Chinese schizophrenia patients

10 July 2024

408

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Further evidence for the association between 5-HT2C receptor gene polymorphisms and extrapyramidal side effects in male schizophrenic patients

10 July 2024

409

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

The CNR1 gene as a pharmacogenetic factor for antipsychotics rather than a susceptibility gene for schizophrenia

10 July 2024

410

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia

10 July 2024

411

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Relationship between three serotonin receptor subtypes (HTR3A, HTR2A and HTR4) and treatment-resistant schizophrenia in the Japanese population

10 July 2024

413

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Manganese superoxide dismutase gene Ala-9Val polymorphism might be related to the severity of abnormal involuntary movements in Korean schizophrenic patients

10 July 2024

414

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

No association between the brain-derived neurotrophic factor gene Val66Met polymorphism and tardive dyskinesia in schizophrenic patients

10 July 2024

415

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association study between antipsychotics- induced restless legs syndrome and polymorphisms of dopamine D1, D2, D3, and D4 receptor genes in schizophrenia

10 July 2024

416

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Possible association between the -2548A/G polymorphism of the leptin gene and olanzapine-induced weight gain.

10 July 2024

417

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting

10 July 2024

418

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

G-protein gene 825C>T polymorphism is associated with response to clozapine in Brazilian schizophrenics

10 July 2024

419

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Naturalistic pharmacogenetic study of treatment resistance to typical neuroleptics in European-Brazilian schizophrenics

10 July 2024

420

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Taq1A polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole

10 July 2024

421

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Polymorphism of dopamine D2 receptor (TaqIA, TaqIB, and-141C Ins/Del) and dopamine degradation enzyme (COMT G158A, A-278G) genes and extrapyramidal symptoms in patients with schizophrenia and bipolar disorders

10 July 2024

422

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

RGS4 polymorphisms predict clinical manifestations and responses to risperidone treatment in patients with schizophrenia

10 July 2024

423

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Effect of a ciliary neurotrophic factor polymorphism on schizophrenia symptom improvement in an iloperidone clinical trial

10 July 2024

424

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

The coding-synonymous polymorphism rs1045280 (Ser280Ser) in beta-arrestin 2 (ARRB2) gene is associated with tardive dyskinesia in Chinese patients with schizophrenia

10 July 2024

425

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Pharmacogenetic study of atypical antipsychotic drug response: involvement of the norepinephrine transporter gene.

10 July 2024

426

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Zhong nan da xue xue bao yi xue ban

10 July 2024

427

33

316

Mou

2008

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

TAAR6 variation effect on clinic presentation and outcome in a sample of schizophrenic in-patients: an open label study.

10 July 2024

428

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Lack of association between the -759C/T polymorphism of the 5-HT2C receptor gene and olanzapine-induced weight gain among Korean schizophrenic patients

10 July 2024

429

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Zhong nan da xue xue bao yi xue ban

10 July 2024

430

33

312

Shao

2008

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Functional polymorphism of the human multidrug resistance gene (MDR1) and polydipsia-hyponatremia in schizophrenia

10 July 2024

431

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia.

10 July 2024

432

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association study of GSK3 gene polymorphisms with schizophrenia and clozapine response

10 July 2024

433

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Associations of SNAP-25 polymorphisms with cognitive dysfunctions in Caucasian patients with schizophrenia during a brief trail of treatment with atypical antipsychotics

10 July 2024

434

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Genetic correlates of olanzapine-induced weight gain in schizophrenia subjects from north India: role of metabolic pathway genes

10 July 2024

435

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

The --1019 C/G polymorphism of the 5-HT(1)A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients.

10 July 2024

436

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Model-based gene selection shows engrailed 1 is associated with antipsychotic response

10 July 2024

437

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

BDNF gene is a genetic risk factor for schizophrenia and is related to the chlorpromazine-induced extrapyramidal syndrome in the Chinese population

10 July 2024

438

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Effects of the dopamine D3 receptor (DRD3) gene polymorphisms on risperidone response: a pharmacogenetic study

10 July 2024

439

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Genetic study of eight AKT1 gene polymorphisms and their interaction with DRD2 gene polymorphisms in tardive dyskinesia

10 July 2024

440

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis

10 July 2024

441

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

A candidate gene study of Tardive dyskinesia in the CATIE schizophrenia trial

10 July 2024

442

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Tardive dyskinesia and DRD3, HTR2A and HTR2C gene polymorphisms in Russian psychiatric inpatients from Siberia.

10 July 2024

443

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Lack of association between antipsychotic-induced Parkinsonism or its subsymptoms and rs4606 SNP of RGS2 gene in African-Caribbeans and the possible role of the medication: the Curacao extrapyramidal syndromes study X.

10 July 2024

444

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Delusion symptoms and response to antipsychotic treatment are associated with the 5-HT2A receptor polymorphism (102T/C) in Alzheimer's disease: a 3-year follow-up longitudinal study.

10 July 2024

445

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Lack of association between DRD3 gene polymorphism and response to clozapine in Turkish schizoprenia patients.

10 July 2024

446

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Leptin gene -2548G/A variants predict risperidone-associated weight gain in children and adolescents

10 July 2024

447

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

HTR2A A-1438G/T102C polymorphisms predict negative symptoms performance upon aripiprazole treatment in schizophrenic patients.

10 July 2024

448

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Effects of the DRD3 Ser9Gly polymorphism on aripiprazole efficacy in schizophrenic patients as modified by clinical factors

10 July 2024

449

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

ABCB1 polymorphisms are associated with clozapine plasma levels in psychotic patients

10 July 2024

450

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Relationship between response to risperidone, plasma concentrations of risperidone and CYP3A4 polymorphisms in schizophrenia patients.

10 July 2024

451

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms.

10 July 2024

452

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Olanzapine-induced weight gain is associated with the -759C/T and -697G/C polymorphisms of the HTR2C gene.

10 July 2024

453

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Further evidence for association of the RGS2 gene with antipsychotic-induced parkinsonism: protective role of a functional polymorphism in the 3'-untranslated region

10 July 2024

454

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Polymorphisms of the LEP- and LEPR gene and obesity in patients using antipsychotic medication.

10 July 2024

455

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine

10 July 2024

456

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association studies of catechol-O-methyltransferase (COMT) gene with schizophrenia and response to antipsychotic treatment.

10 July 2024

457

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

The association of olanzapine-induced weight gain with peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism in patients with schizophrenia.

10 July 2024

458

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine.

10 July 2024

459

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association study between glutathione S-transferase GST-M1, GST-T1, and GST-P1 polymorphisms and tardive dyskinesia.

10 July 2024

460

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study

10 July 2024

461

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association of the glutamate transporter gene SLC1A1 with atypical antipsychotics-induced obsessive-compulsive symptoms

10 July 2024

462

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome.

10 July 2024

463

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects?

10 July 2024

464

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

No association of serotonin transporter polymorphism (5-HTTVNTR and 5-HTTLPR) with characteristics and treatment response to atypical antipsychotic agents in schizophrenic patients

10 July 2024

465

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Analysis of genetic variations in the RGS9 gene and antipsychotic-induced tardive dyskinesia in schizophrenia

10 July 2024

466

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Functional serotonin 1A receptor variant influences treatment response to atypical antipsychotics in schizophrenia

10 July 2024

467

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study

10 July 2024

468

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Genetic association of BDNF val66met and GSK-3beta-50T/C polymorphisms with tardive dyskinesia.

10 July 2024

469

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association of the alpha 2A adrenergic receptor -1291C/G polymorphism and antipsychotic-induced weight gain in European-Americans.

10 July 2024

470

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia

10 July 2024

471

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association analysis of serotonin receptor 7 gene (HTR7) and risperidone response in Chinese schizophrenia patients

10 July 2024

472

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

The role of dopamine D3, 5-HT2A and 5-HT2C receptor variants as pharmacogenetic determinants in tardive dyskinesia in African-Caribbean patients under chronic antipsychotic treatment: Curacao extrapyramidal syndromes study IX.

10 July 2024

473

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association study of tardive dyskinesia and five DRD4 polymorphisms in schizophrenia patients

10 July 2024

474

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Oxidative stress in tardive dyskinesia: genetic association study and meta-analysis of NADPH quinine oxidoreductase 1 (NQO1) and Superoxide dismutase 2 (SOD2, MnSOD) genes

10 July 2024

475

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

The efficacies of clozapine and haloperidol in refractory schizophrenia are related to DTNBP1 variation

10 July 2024

476

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients

10 July 2024

478

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Genomewide association study of movement-related adverse antipsychotic effects

10 July 2024

479

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study

10 July 2024

480

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia

10 July 2024

481

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research

10 July 2024

482

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis.

10 July 2024

483

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs

10 July 2024

484

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Dopamine partial agonists: a new class of antipsychotic

10 July 2024

485

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone

10 July 2024

486

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia

10 July 2024

487

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers

10 July 2024

488

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

A functionally deficient DRD2 variant [Ser311Cys] is not linked to alcoholism and substance abuse

10 July 2024

489

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions

10 July 2024

490

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system

10 July 2024

491

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Antipsychotic-induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: a meta analysis

10 July 2024

492

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Role of serotonin in the action of atypical antipsychotic drugs

10 July 2024

493

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Serotonin receptors: their key role in drugs to treat schizophrenia

10 July 2024

494

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Molecular biology of serotonin receptors structure and function at the molecular level

10 July 2024

495

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response.

10 July 2024

496

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype

10 July 2024

497

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysis

10 July 2024

498

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Public health. A case study of personalized medicine.

10 July 2024

500

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors

10 July 2024

501

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Overview of biomarkers and surrogate endpoints in drug development

10 July 2024

502

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use.

10 July 2024

504

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Pharmacogenetics in psychiatry: are we ready for widespread clinical use?

10 July 2024

505

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement

10 July 2024

506

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective

10 July 2024

507

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

Metabolic drug interactions with newer antipsychotics: a comparative review.

10 July 2024

508

1 reference

https://api.crossref.org/works/10.1016/J.CLL.2010.07.004

10 July 2024

Identifiers

1 reference

14 April 2018

release_exbxzwoberfo3izvlva6de6g3u

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/exbxzwoberfo3izvlva6de6g3u

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

14 April 2018